Key Takeaways Corcept Therapeutics' (CORT) sole marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing's syndrome, has been witnessing steady demand. Currently, the company's top line is primarily driven by Korlym sales. Korlym recorded sales of $164.9 million, up around 5% year over year, driven by its established Cushing's syndrome franchise, with management highlighting rising demand for Korlym. Per management, March and April marked all-time highs in the number of patients ...